NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01550055,Study of CMAB009 to Treat KRAS Wild Type Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT01550055,CRC009,COMPLETED,The primary purpose of this study is to evaluate the clinical response and safety of CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients,NO,Metastatic Colorectal Cancer,DRUG: CMAB009 plus Irinotecan|DRUG: Irinotecan-only and sequential-CMAB009,"Overall response rate, Tumor response was evaluated every 6 weeks and confirmed at least 4 weeks later, Time to progression, assessed up to two years","Progression-free Survival, The study was designed to evaluate the PFS as second end point, progression-free survival is defined as the period from date of randomization to date of disease progression, Time to progression, assessed up to two years",,Shanghai Zhangjiang Biotechnology Limited Company,"Shanghai Biomabs Pharmaceutical Co., Ltd.",ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,512,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,CMAB009mCRCⅡ/Ⅲ|CMAB009,2009-05-31,2012-12-23,2015-07-23,2012-03-09,,2019-04-10,,
